Elez, Elena
Pericay, Carles
Valladares-Ayerbes, Manuel
Bando, Inmaculada
Safont, Maria Jose
Gallego, Javier
Grávalos, Cristina
Arrivi, Antonio
Carrato, Alfredo
Conde, Verónica
Ortiz, Maria José
López, Carlos
Alonso, Beatriz
Ruiz de Mena, Inmaculada
Díaz-Rubio, Eduardo
Tabernero, Josep
Aranda, Enrique
Funding for this research was provided by:
Amgen S.A.
Article History
Received: 7 December 2018
Accepted: 11 July 2019
First Online: 31 July 2019
Competing interests
: M.V.A. has received payment for advisory roles from Amgen, Merck and Sanofi, honoraria from Bayer, Servier and Roche, payment for research funding from Roche and other remuneration from Roche, Merck and Amgen. V.C. has received honoraria from Amgen. A.C. has received honoraria for advisory roles from Bayer, Shire and Celgene. E.A. has received honoraria for advisory roles from Amgen, Bayer, Celgene, Merck, Roche, Sanofi. E.E. has a scientific consultancy role for Array Biopharma, Merck Serono, F. Hoffmann-La Roche Ltd, Sanofi, Servier, Amgen. J.T. has scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Inc., Genmab A/S, Halozyme, Imugene Limited, Inflection Biosciences Limited, Ipsen, Kura Oncology, Lilly, MSD, Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael Pharmaceuticals, F. Hoffmann-La Roche Ltd, Sanofi, SeaGen, Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS and Roche Diagnostics. E.D.R. has received honoraria for advisory roles or speaker from Roche, Merck Serono, Amgen, Bayer, MSD, Genomica and research funding from Roche, Merck-Serono, Amgen, Astra Zeneca. C.L. has received honoraria from, performed consultancy for and/or received research funding from Roche, Merc, Sanofi, Novartis, Pfizer, Eisai, Ipsen, Bayer, AstraZeneca, Servier, Amgen, Bayer, MSD and Celgene. The remaining authors declare no competing interests.
: This study was approved by the local ethics committee (the independent ethics committee of hospital Universitari Vall d’Hebrón, as the Clinical Research Ethics Committee Coordinating Center) and the Spanish Health Authorities and was conducted in accordance with the principles of the Declaration of Helsinki. Patients were instructed about the experimental procedures of the study and enrolled after signature of the informed consent.
: This work was supported by Amgen S.A, who did not have any role in study design; collection, analysis and interpretation of data; writing the report, or the decision to submit the report for publication.
: Data and results are available at the Department of Medical Oncology, Vall d’Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain.